ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. On average, analysts expect ArriVent BioPharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Price Performance

AVBP stock traded up $1.11 during trading on Monday, reaching $31.10. 58,337 shares of the stock traded hands, compared to its average volume of 497,838. The business’s 50 day moving average price is $25.52 and its 200-day moving average price is $22.81. ArriVent BioPharma has a 52-week low of $16.10 and a 52-week high of $32.14. The firm has a market capitalization of $1.44 billion, a PE ratio of -7.05 and a beta of 1.51.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new position in ArriVent BioPharma during the 1st quarter valued at $266,000. Woodline Partners LP boosted its stake in ArriVent BioPharma by 0.4% during the 1st quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock valued at $2,706,000 after acquiring an additional 576 shares during the last quarter. Jane Street Group LLC bought a new position in ArriVent BioPharma during the 1st quarter valued at $189,000. Legal & General Group Plc boosted its stake in ArriVent BioPharma by 8.8% during the 2nd quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock valued at $322,000 after acquiring an additional 1,197 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in ArriVent BioPharma during the 2nd quarter valued at $206,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a research report on Friday, March 6th. Citigroup boosted their price target on ArriVent BioPharma from $33.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Monday, April 20th. BTIG Research assumed coverage on ArriVent BioPharma in a research note on Thursday, March 12th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, HC Wainwright boosted their price objective on ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.00.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.